Pfizer Inc. (NYSE:PFE) Shares Bought by Bard Financial Services Inc.

Bard Financial Services Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 518,347 shares of the biopharmaceutical company’s stock after purchasing an additional 838 shares during the quarter. Pfizer accounts for 1.6% of Bard Financial Services Inc.’s holdings, making the stock its 9th largest position. Bard Financial Services Inc.’s holdings in Pfizer were worth $13,752,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Private Advisor Group LLC increased its stake in Pfizer by 12.8% in the second quarter. Private Advisor Group LLC now owns 735,962 shares of the biopharmaceutical company’s stock valued at $20,592,000 after acquiring an additional 83,754 shares during the last quarter. Lake Street Advisors Group LLC grew its position in Pfizer by 29.3% in the second quarter. Lake Street Advisors Group LLC now owns 35,090 shares of the biopharmaceutical company’s stock valued at $982,000 after acquiring an additional 7,955 shares during the last quarter. Wakefield Asset Management LLLP bought a new position in shares of Pfizer in the second quarter worth about $454,000. Strategic Financial Concepts LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $38,000. Finally, Asset Dedication LLC boosted its position in Pfizer by 4.2% in the second quarter. Asset Dedication LLC now owns 16,695 shares of the biopharmaceutical company’s stock valued at $467,000 after buying an additional 669 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.15.

Pfizer Stock Up 2.4 %

Shares of PFE traded up $0.63 during trading hours on Monday, reaching $27.22. The stock had a trading volume of 21,853,763 shares, compared to its average volume of 28,916,898. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market capitalization of $154.26 billion, a price-to-earnings ratio of 36.78, a P/E/G ratio of 0.63 and a beta of 0.65. The firm has a 50-day simple moving average of $26.33 and a 200 day simple moving average of $28.08. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.32%. Pfizer’s dividend payout ratio (DPR) is 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.